Oneg Hakarmel manufactures and sells products for orthopedic surgery, vascular surgery, and emergency medicine. Its core patent-protected technology is a line of single-use devices designed to quickly and effectively displace blood from the limbs and block its re-entry. The company's HemaClear line of sterile surgical products is widely used to create a bloodless surgical field. The company has also developed the EED product line for use in emergency medicine. The EED system is used to auto-transfuse a patients own blood from their limbs into central circulation during severe shock or cardiopulmonary resuscitation. HemaClear is FDA listed and CE marked. In November 2018, the company launched HemaShock, an emergency auto-transfusion tourniquet that is used to squeeze blood out of the legs (and from the arms as well, if necessary) and block the re-entry of arterial blood flow into those limbs. This can be done quickly by a single caregiver, even during transport. The HemaShock is indicated for use in patients who have very low systolic blood pressure (less than 80 mm Hg) due to hemodynamic shock or cardiac arrest.